Key facts
- Genbioma’s last known valuation is $1.9M (Jan 2021).
- It has raised $1.5M.
- Notable investors include Clave (Pamplona), Sociedad de Desarrollo de Navarra, CaixaBank, KMZERO (Valencia), Scale the Impact — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Genbioma
- ·The full record, as it builds
Funding rounds
No funding rounds for Genbioma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Genbioma
Developer of postbiotic therapeutics designed to support metabolic health in conditions related to glucose regulation, weight management, and cardiovascular function. The company offers microbiome research capabilities, postbiotic development, and rapid bacterial strain assessment using a C. elegans-based model, enabling healthcare and life sciences organizations to identify and develop candidates with relevant metabolic health effects more efficiently.
- Sector
- Healthcare
- HQ
- Noáin, Spain
- Founded
- 2019
- Employees
- 7
- Website
- genbioma.com/
- Ownership
- Privately Held (backing)
Genbioma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genbioma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genbioma in its N-PORT filings yet. We sweep new filings monthly.